Review of AI and in silico methods for senolytic food peptides
This review evaluates AI and in silico methods in research on senolytic food peptides from soy, dairy, legumes and marine sources, and notes that many peptides described in the literature are senescence-associated candidates awaiting mechanistic validation, not confirmed senolytics or senomorphics. [1]
Automatic summary · not editorially reviewed
The key findings
The review evaluates AI and in silico methods in senolytic food peptide research, distinguishing discovery, prioritization and unverified senescence relevance. [1]
Discovery pipelines are evaluated across soy, dairy, legumes and marine sources, addressing pharmacokinetics, bioavailability, senescence heterogeneity, gastrointestinal stability and bitterness. [1]
Many peptides in the current literature are best characterized as senescence-associated candidates awaiting mechanistic validation, not confirmed senolytics or senomorphics. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Food-derived bioactive peptides from soy, dairy, legumes and marine sources, discussed in the reviewed literature
- Summary based on
- Study abstract
- Original publication
- September 25, 2026
Senolytic food peptides and AI review scope
The review addresses cellular senescence, described as characterized by the senescence-associated secretory phenotype and as a primary driver of age-related tissue dysfunction. Because synthetic senolytics have raised concerns about systemic toxicity, the authors say focus has shifted toward sustainable alternatives such as food-derived bioactive peptides. The review evaluates AI and in silico methods in senolytic food peptide research and distinguishes discovery, prioritization and unverified senescence relevance.
Supporting source [1]
Pipelines across soy, dairy, legumes and marine sources
The authors evaluate discovery pipelines across soy, dairy, legumes and marine sources. They address pharmacokinetics, bioavailability, senescence heterogeneity, gastrointestinal stability and bitterness. They also point to a lack of standardized replicative and therapy-induced experimental senescence models.
Supporting source [1]
Candidates awaiting validation; proposed future models
The review states that a substantial proportion of peptides discussed in the current literature are best characterized as senescence-associated candidates that await mechanistic validation, rather than as confirmed senolytics or senomorphics. For future research, the authors say priority must be given to bioengineered 3D human tissue models and long-term clinical validation. These are proposed directions, not established results.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no primary experiments, sample sizes or clinical outcomes, and the proposed 3D tissue models and long-term clinical validation are future directions, not established findings.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Lee CC, Suttikhana I, Ashaolu TJ. · europepmc.org · September 25, 2026